243 related articles for article (PubMed ID: 21104730)
1. Gender medicine and drug eluting coronary stents.
Kornowski R
Catheter Cardiovasc Interv; 2010 Nov; 76(6):814-6. PubMed ID: 21104730
[No Abstract] [Full Text] [Related]
2. Angiographic restenosis and clinical recurrence after sirolimus- and paclitaxel-eluting stent implantation.
Vlaar PJ; Zijlstra F
JACC Cardiovasc Interv; 2009 Aug; 2(8):776-8. PubMed ID: 19695547
[No Abstract] [Full Text] [Related]
3. A critical appraisal of the Janus carbostent.
Kornowski R
Catheter Cardiovasc Interv; 2009 Feb; 73(2):249-50. PubMed ID: 19156897
[No Abstract] [Full Text] [Related]
4. Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results.
Brown RA; Williams M; Barker CM; Mauri L; Meredith IT; Fajadet J; Wijns W; Leon MB; Kandzari DE
Catheter Cardiovasc Interv; 2010 Nov; 76(6):804-13. PubMed ID: 20815043
[TBL] [Abstract][Full Text] [Related]
5. Stent strut fracture: seeing is believing.
Carter AJ
Catheter Cardiovasc Interv; 2008 Apr; 71(5):619-20. PubMed ID: 18360854
[No Abstract] [Full Text] [Related]
6. A generation 2.5 drug-eluting stent?
Ellis SG
JACC Cardiovasc Interv; 2009 Oct; 2(10):986-8. PubMed ID: 19850259
[No Abstract] [Full Text] [Related]
7. Treating the left main bifurcation lesion: the "three stent solution".
Uretsky BF
Catheter Cardiovasc Interv; 2009 Jan; 73(1):42-3. PubMed ID: 19089935
[No Abstract] [Full Text] [Related]
8. Late restenosis following sirolimus-eluting stent implantation.
Kuriyama N; Kobayashi Y; Nakama T; Mine D; Nishihira K; Shimomura M; Nomura K; Ashikaga K; Matsuyama A; Shibata Y
JACC Cardiovasc Interv; 2011 Jan; 4(1):123-8. PubMed ID: 21251639
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
[TBL] [Abstract][Full Text] [Related]
10. The process of bringing new drug-eluting stents to market will they see the light of day?
Holmes DR; Patel M
JACC Cardiovasc Interv; 2008 Oct; 1(5):533-4. PubMed ID: 19463355
[No Abstract] [Full Text] [Related]
11. My stent is better than your stent...Or is it?
Bates ER; Menees DS
JACC Cardiovasc Interv; 2011 May; 4(5):551-3. PubMed ID: 21596328
[No Abstract] [Full Text] [Related]
12. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
[TBL] [Abstract][Full Text] [Related]
13. The artisan approach for stenting bifurcation lesions.
Colombo A; Latib A
JACC Cardiovasc Interv; 2010 Jan; 3(1):66-7. PubMed ID: 20129571
[No Abstract] [Full Text] [Related]
14. Restenosis following thin-strut bare-metal stents versus thick-strut drug-eluting stents.
Moliterno DJ
Catheter Cardiovasc Interv; 2007 May; 69(6):799-800. PubMed ID: 17377984
[No Abstract] [Full Text] [Related]
15. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
[TBL] [Abstract][Full Text] [Related]
16. Percutaneous UPLM revascularisation: the time has come.
Goyal BK
Catheter Cardiovasc Interv; 2010 Jun; 75(7):1050. PubMed ID: 20517967
[No Abstract] [Full Text] [Related]
17. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus-eluting stent fractures leading to restenosis in cardiac allograft vasculopathy.
Cilingiroglu M; Chilakapati V; Dunlap S; Leesar MA
Cardiovasc Revasc Med; 2010; 11(2):120-3. PubMed ID: 20347805
[TBL] [Abstract][Full Text] [Related]
19. Long-term complication after LM bifurcation treatment.
Wainstein MV; Ribeiro JP
Catheter Cardiovasc Interv; 2010 Jun; 75(7):1045-9. PubMed ID: 20146313
[TBL] [Abstract][Full Text] [Related]
20. If I've heard it once, I've heard it (not yet) a hundred times.
Butman SM
Catheter Cardiovasc Interv; 2011 Mar; 77(4):502. PubMed ID: 21351224
[No Abstract] [Full Text] [Related]
[Next] [New Search]
